Terms: = Breast cancer AND TRIM27, DASS-46L4_6, RFP, 5987, ENSG00000234495, RNF76 AND Clinical Outcome
688 results:
1. Tumor budding in breast carcinoma: A systematic review and meta-analysis.
Buch A; Khan U; Rathod H; Jain K; Dwivedi A; Rajesh A
J Cancer Res Ther; 2023 Oct; 19(7):1697-1713. PubMed ID: 38376268
[TBL] [Abstract] [Full Text] [Related]
2. Molecular features of luminal breast cancer defined through spatial and single-cell transcriptomics.
Yoshitake R; Mori H; Ha D; Wu X; Wang J; Wang X; Saeki K; Chang G; Shim HJ; Chan Y; Chen S
Clin Transl Med; 2024 Jan; 14(1):e1548. PubMed ID: 38282415
[TBL] [Abstract] [Full Text] [Related]
3. Adrenal incidentalomas, cortisol secretion and cancer: is there a real crosstalk?
Herrera-Martínez AD; Román ÁR; Corrales EP; Idrobo C; Ramírez PP; Rojas PM; Lázaro CR; Araujo-Castro M
Front Endocrinol (Lausanne); 2023; 14():1335202. PubMed ID: 38264281
[TBL] [Abstract] [Full Text] [Related]
4. Effectiveness and toxicity of five-fraction prone accelerated partial breast irradiation.
Hardy-Abeloos C; Xiao J; Oh C; Barbee D; Shah B; Maisonet O; Perez C; Adams S; Schnabel F; Axelrod D; Guth A; Karp N; Cahlon O; Gerber N
Breast Cancer Res Treat; 2024 Apr; 204(3):485-495. PubMed ID: 38183516
[TBL] [Abstract] [Full Text] [Related]
5. Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative breast cancer.
Coakley M; Villacampa G; Sritharan P; Swift C; Dunne K; Kilburn L; Goddard K; Pipinikas C; Rojas P; Emmett W; Hall P; Harper-Wynne C; Hickish T; Macpherson I; Okines A; Wardley A; Wheatley D; Waters S; Palmieri C; Winter M; Cutts RJ; Garcia-Murillas I; Bliss J; Turner NC
Clin Cancer Res; 2024 Feb; 30(4):895-903. PubMed ID: 38078899
[TBL] [Abstract] [Full Text] [Related]
6. A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive/HER2-negative Advanced or Metastatic breast cancer.
Cescon DW; Hilton J; Morales Murilo S; Layman RM; Pluard T; Yeo B; Park IH; Provencher L; Kim SB; Im YH; Wyce A; Krishnatry AS; Hicks K; Zhang Q; Barbash O; Khaled A; Horner T; Dhar A; Oliveira M; Sparano JA
Clin Cancer Res; 2024 Jan; 30(2):334-343. PubMed ID: 37992310
[TBL] [Abstract] [Full Text] [Related]
7. clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan.
Baba T; Kusumoto M; Kato T; Kurihara Y; Sasaki S; Oikado K; Saito Y; Endo M; Fujiwara Y; Kenmotsu H; Sata M; Takano T; Kato K; Hirata K; Katagiri T; Saito H; Kuwano K
Int J Clin Oncol; 2023 Dec; 28(12):1585-1596. PubMed ID: 37787866
[TBL] [Abstract] [Full Text] [Related]
8. Clinicopathological and prognostic value of TIL and PD L1 in triple negative breast carcinomas.
Uğurluoğlu C; Yormaz S
Pathol Res Pract; 2023 Oct; 250():154828. PubMed ID: 37778126
[TBL] [Abstract] [Full Text] [Related]
9. clinical and prognostic role of sarcopenia based on masticatory muscle index on MR images in patients with extranodal natural killer/T cell lymphoma, nasal type.
Xu T; Li Y; Liu Y; Ning B; Wu H; Wei Y
Ann Hematol; 2023 Dec; 102(12):3521-3532. PubMed ID: 37702822
[TBL] [Abstract] [Full Text] [Related]
10. Feasibility and efficacy of ultrasound-guided high-intensity focused ultrasound of breast fibroadenoma.
Liang M; Zhang Z; Zhang C; Chen R; Xiao Y; Li Z; Li T; Liu Y; Ling L; Xie H; Chen L; Liu X; Wang S; Xia T
Int J Hyperthermia; 2023; 40(1):2240548. PubMed ID: 37544652
[TBL] [Abstract] [Full Text] [Related]
11. Early changes in soluble intracellular adhesion molecule-1 as prognostic biomarkers to immune checkpoint inhibitor.
Ji D; Jiang S; Zhang Q; Wang YK; Zhang J; Shen W; Li W; Liu R; Wang J; Mavis C; Gu JJ; Hu X
Clin Transl Sci; 2023 Aug; 16(8):1396-1407. PubMed ID: 37317057
[TBL] [Abstract] [Full Text] [Related]
12. Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial.
Harbeck N; Fasching PA; Wuerstlein R; Degenhardt T; Lüftner D; Kates RE; Schumacher J; Räth P; Hoffmann O; Lorenz R; Decker T; Reinisch M; Göhler T; Staib P; Gluz O; Schinköthe T; Schmidt M;
Ann Oncol; 2023 Aug; 34(8):660-669. PubMed ID: 37201751
[TBL] [Abstract] [Full Text] [Related]
13. Epidemiology and a Predictive Model of Prognosis Index Based on Machine Learning in Primary breast Lymphoma: Population-Based Study.
Yu Y; Xu Z; Shao T; Huang K; Chen R; Yu X; Zhang J; Han H; Song C
JMIR Public Health Surveill; 2023 Jun; 9():e45455. PubMed ID: 37169516
[TBL] [Abstract] [Full Text] [Related]
14. DNA aneuploidy identifies a subset of Luminal subtype breast carcinoma patients with worse clinical outcome.
Pinto AE; Matos J; Pereira T; Silva GL; André S
Pathol Res Pract; 2023 Jun; 246():154513. PubMed ID: 37167811
[TBL] [Abstract] [Full Text] [Related]
15. A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study.
Gravis G; Marino P; Olive D; Penault-LLorca F; Delord JP; Simon C; Lamrani-Ghaouti A; Sabatier R; Ciccolini J; Boher JM
BMC Cancer; 2023 May; 23(1):393. PubMed ID: 37131154
[TBL] [Abstract] [Full Text] [Related]
16. Reducing the Use of Frozen Section for Sentinel Node Biopsy in breast Carcinoma: Feasibility and outcome.
Susini T; Nesi I; Renda I; Giani M; Nori J; Vanzi E; Bianchi S
Anticancer Res; 2023 May; 43(5):2161-2170. PubMed ID: 37097648
[TBL] [Abstract] [Full Text] [Related]
17. The role of p53 and ki67 in predicting clinical outcome in breast cancer patients.
Lalkota BP; Srinivasa BJ; Swamy MV; Hazarika D; Jeet BM; Jyothi K; Ghosh M; Sayeed SM; Nasiruddin M; Naik R
J Cancer Res Ther; 2023; 19(2):208-213. PubMed ID: 37006059
[TBL] [Abstract] [Full Text] [Related]
18. Investigating the clinical impact of dose-banding for weekly paclitaxel in patients with breast cancer: A retrospective and monocentric study.
Puisset F; Le Louedec F; Dalenc F; Verguet L; De Maio E; Lacaze JL; Montastruc M; Ung M; Vinson C; Perriat S; Pacher S; Chatelut E; Koning MW
Br J Clin Pharmacol; 2023 Jul; 89(7):2283-2294. PubMed ID: 36854898
[TBL] [Abstract] [Full Text] [Related]
19. Targeting RNA N6-methyladenosine to synergize with immune checkpoint therapy.
Zhou X; Li C; Chen T; Li W; Wang X; Yang Q
Mol Cancer; 2023 Feb; 22(1):36. PubMed ID: 36810108
[TBL] [Abstract] [Full Text] [Related]
20. Treatment and outcome in metastatic lobular breast cancer in the prospective German research platform OPAL.
Thill M; Zahn MO; Welt A; Stickeler E; Nusch A; Fietz T; Rauh J; Wetzel N; Kruggel L; Jänicke M; Marschner N; Harbeck N; Wöckel A; Decker T;
Breast Cancer Res Treat; 2023 Apr; 198(3):545-553. PubMed ID: 36807725
[TBL] [Abstract] [Full Text] [Related]
[Next]
